DGX Share Price | Quest Diagnostics, Inc. Stock Analysis & Recommendation

Q: How big is Quest Diagnostics, Inc.?

Market Cap: As of Jun 18, Quest Diagnostics, Inc. has a market capitalization of 29,103.62 million, classifying it as a Mid Cap company.Recent Quarterly Performance: For the latest four quarters, Quest Diagnostics, Inc. reported net sales of 10,158.00 million and a net profit of 943.00 million.Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 6,778.00 million, while total assets were reported at 16,153.00 million.

Q: What does Quest Diagnostics, Inc. do?

Overview:Quest Diagnostics, Inc. is a provider of diagnostic information services operating in the Miscellaneous industry and is categorized as a mid-cap company.Financial Snapshot:Most recent Net Sales: 2,652 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 234 Million (Quarterly Results - Mar 2025) Market-cap: USD 29,103.62 Million (Mid Cap)Key Metrics:P/E: 28.00 Dividend Yield: 117.62% Debt Equity: 0.84 Return on Equity: 14.38% Price to Book: 4.20 Contact Details:Address: 500 Plaza Dr, SECAUCUS NJ: 07094-3619 Tel: 1 973 5202700 Website: https://www.questdiagnostics.com/

Q: Is Quest Diagnostics, Inc. overvalued or undervalued?

As of 30 June 2025, the valuation grade for Quest Diagnostics, Inc. has moved from attractive to fair. This suggests that the company is fairly valued at present. Key valuation ratios include a P/E ratio of 28, an EV to EBITDA of 17.29, and a Price to Book Value of 4.09. In comparison, peers such as IQVIA Holdings, Inc. have a higher P/E of 36.39, while Laboratory Corp. of America Holdings has a P/E of 29.20, indicating that Quest Diagnostics is positioned competitively within its industry.In terms of recent performance, Quest Diagnostics has achieved a year-to-date return of 21.52%, significantly outperforming the S&P 500's 12.22% during the same period, although it lags behind the S&P 500 over longer horizons like 3 years and 5 years. Overall, the current valuation metrics suggest that Quest Diagnostics is fairly valued in the market.

Q: Is Quest Diagnostics, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Quest Diagnostics, Inc. has changed from bullish to mildly bullish. The weekly and monthly MACD indicators are bullish, while the Bollinger Bands show a mildly bullish stance in both time frames. The daily moving averages also indicate a mildly bullish trend. However, the RSI shows no signal on both weekly and monthly charts, and Dow Theory indicates no trend in either time frame. In terms of performance, Quest Diagnostics has outperformed the S&P 500 year-to-date and over the past year, with returns of 18.28% and 18.33% respectively, compared to the S&P 500's 14.18% and 17.82%. However, it has underperformed over longer periods, particularly in the 3-year and 5-year comparisons. Overall, the current technical stance is mildly bullish, supported by several bullish indicators, despite some mixed signals.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.19 M

Shareholding (Dec 2025)

FII

20.37%

Held by 354 FIIs

DII

38.33%

Held by 56 DIIs

Promoter

0.04%

How big is Quest Diagnostics, Inc.?

22-Jun-2025

As of Jun 18, Quest Diagnostics, Inc. has a market capitalization of $29.1 billion, with recent net sales of $10.2 billion and a net profit of $943 million.

View full answer

What does Quest Diagnostics, Inc. do?

22-Jun-2025

Quest Diagnostics, Inc. is a mid-cap provider of diagnostic information services, with recent net sales of $2.65 billion and a net profit of $234 million. Key financial metrics include a P/E ratio of 28.00 and a dividend yield of 117.62%.

View full answer

Who are in the management team of Quest Diagnostics, Inc.?

22-Jun-2025

As of March 2022, the management team of Quest Diagnostics, Inc. includes Stephen Rusckowski (Chairman, President, and CEO), Dr. Daniel Stanzione (Lead Independent Director), and several Independent Directors: Vicky Gregg, Wright Lassiter, Timothy Main, and Denise Morrison. They oversee the company's strategic direction and operations.

View full answer

Is Quest Diagnostics, Inc. overvalued or undervalued?

20-Sep-2025

As of June 30, 2025, Quest Diagnostics is fairly valued with a P/E ratio of 28, an EV to EBITDA of 17.29, and a Price to Book Value of 4.09, while achieving a year-to-date return of 21.52%, outperforming the S&P 500's 12.22%.

View full answer

Is Quest Diagnostics, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Quest Diagnostics has a mildly bullish technical trend, supported by bullish MACD and moving averages, while outperforming the S&P 500 year-to-date and over the past year, despite mixed signals in longer-term performance.

View full answer

Compare Quest Diagnostics, Inc. with Similar Stocks

Laboratory Corp. of America Holdings IQVIA Holdings, Inc.Astrana Health, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

High Management Efficiency with a high ROCE of 17.67%

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 10.91

Poor long term growth as Operating profit has grown by an annual rate 6.70% of over the last 5 years

Positive results in Jun 25

With ROCE of 11.44%, it has a expensive valuation with a 2.68 Enterprise value to Capital Employed

Mojo Parameters

Stock DNA

Industry

Miscellaneous

Market cap

USD 32,003 Million (Mid Cap)

P/E

28.00

Industry P/E

Dividend Yield

28.89%

Debt Equity

0.76

Return on Equity

15.73%

Price to Book

4.46

Revenue and Profits:

Net Sales:

2,806 Million

(Quarterly Results - Dec 2025)

Net Profit:

256 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

10.85%

6 Months

6.51%

1 Year

13.23%

2 Years

52.38%

3 Years

48.45%

4 Years

34.61%

5 Years

57.14%

Quest Diagnostics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

3.18%

EBIT Growth (5y)

-5.27%

EBIT to Interest (avg)

10.91

Debt to EBITDA (avg)

1.95

Net Debt to Equity (avg)

0.84

Sales to Capital Employed (avg)

0.81

Tax Ratio

22.45%

Dividend Payout Ratio

36.57%

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

17.67%

ROE (avg)

20.41%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.46

EV to EBIT

23.35

EV to EBITDA

18.46

EV to Capital Employed

2.97

EV to Sales

3.39

PEG Ratio

1.68

Dividend Yield

28.89%

ROCE (Latest)

12.73%

ROE (Latest)

15.73%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 151 Schemes (41.25%)

Foreign Institutions

Held by 354 Foreign Institutions (20.37%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -0.36% vs 1.99% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -0.39% vs -12.88% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,806.00",
          "val2": "2,816.00",
          "chgp": "-0.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "536.00",
          "val2": "562.00",
          "chgp": "-4.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "67.00",
          "val2": "69.00",
          "chgp": "-2.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-24.00",
          "val2": "-33.00",
          "chgp": "27.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "256.00",
          "val2": "257.00",
          "chgp": "-0.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "139.30%",
          "val2": "149.10%",
          "chgp": "-0.98%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 11.78% vs 6.70% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 13.76% vs 1.33% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "11,035.00",
          "val2": "9,872.00",
          "chgp": "11.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,173.00",
          "val2": "1,908.00",
          "chgp": "13.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "277.00",
          "val2": "226.00",
          "chgp": "22.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-105.00",
          "val2": "-68.00",
          "chgp": "-54.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,042.00",
          "val2": "916.00",
          "chgp": "13.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "145.30%",
          "val2": "143.30%",
          "chgp": "0.20%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

2,806.00

2,816.00

-0.36%

Operating Profit (PBDIT) excl Other Income

536.00

562.00

-4.63%

Interest

67.00

69.00

-2.90%

Exceptional Items

-24.00

-33.00

27.27%

Consolidate Net Profit

256.00

257.00

-0.39%

Operating Profit Margin (Excl OI)

139.30%

149.10%

-0.98%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is -0.36% vs 1.99% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -0.39% vs -12.88% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

11,035.00

9,872.00

11.78%

Operating Profit (PBDIT) excl Other Income

2,173.00

1,908.00

13.89%

Interest

277.00

226.00

22.57%

Exceptional Items

-105.00

-68.00

-54.41%

Consolidate Net Profit

1,042.00

916.00

13.76%

Operating Profit Margin (Excl OI)

145.30%

143.30%

0.20%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 11.78% vs 6.70% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 13.76% vs 1.33% in Dec 2024

All Annual Results

Company CV

About Quest Diagnostics, Inc.

Quest Diagnostics, Inc.

Miscellaneous

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs). Its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company's services are provided under the Quest Diagnostics brand, but it also provides services under other brands, including AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum and Care360.

Company Coordinates

Company Details

500 Plaza Dr , SECAUCUS NJ : 07094-3619

Tel: 1 973 5202700

https://www.questdiagnostics.com/

Registrar Details